Alimta Example Shows Limitations Of ASCO Value Framework, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ASCO assigns Lilly’s lung cancer drug Alimta a net health benefit score of zero out of 130 in illustrating how its proposed framework for valuing cancer drugs will work.